A biotech company approached Science 37 to develop a virtualized process to evaluate patients who may be eligible for an interventional study with a novel gene therapy program for a very rare, life-altering disease, known as Classic Congenital Adrenal Hyperplasia (CAH) without the need to open countless brick-and-mortar sites to recruit these patients.
Learn how Science 37 Metasite delivered:
- 100+ preliminary eligible patients
- Nearly 50 total consented
- Mobile nursing supporting patients at home for blood collection
- 6+ months of monitoring and engagement